ESR1 and breast carcinoma: Amplification of the gene has been detected in about 15% of breast cancers, while overexpression of cyclin D1 at mRNA and protein levels is seen in up to 50% of primary tumors, mostly ER-positive and well-differentiated tumors [58], [59].